Event Brief
Jan 10, 2026 at 11:02 AM ET
2026: The Year of Obesity Pills and GLP-1 Market Shift
By The BriefBrief
Novo Nordisk's GLP-1 obesity pill is available, with Eli Lilly's rival drug pending U.S. approval.
WHO: Novo Nordisk, Eli Lilly
WHAT: Obesity pills and GLP-1 market developments
WHEN: Jan 9, 2026 at 7:00 PM ET
WHERE: United States
WHY: To address obesity with new oral medications
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Saudi Arabia delays response to UAE leaving Opec
Saudi Arabia
May 1, 2026 at 3:23 PM ET
Amazon faces months of repairs after drone strikes
Amazon
May 1, 2026 at 3:23 PM ET
Minnesota bans fake AI nudes; app makers face $500K
Minnesota
May 1, 2026 at 3:23 PM ET
Page 21426 of 21426
Same format. Every time.
Continue reading — sign in or create a free account with
